Four-year data from the SELECT trial will significantly bolster Novo Nordisk’s (NOVO: N) bid to become the GLP-1 company of choice for payers and prescribers. 15 May 2024
Accord BioPharma—the US specialty division of Intas Pharmaceuticals— has won US Food and Drug Administration (FDA) approval for Hercessi (trastuzumab-strf), a b 9 May 2024
Half of pharma execs are bracing for significant revenue impact from Medicare price negotiations this year, compared to just 22% in 2023, according to research 7 May 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.